News archive
Showing 688 results
March 2011
-
Media Release
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
Phase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149[1]COPD is a progressive and life-threatening lung… -
Media Release
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
January 2011
-
Media Release
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
East Hanover, NJ, January 10, 2011 – Novartis Pharmaceuticals Corporation (Novartis) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks… -
Media Release
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
December 2010
-
Media Release
Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
- In a clinical trial, Amturnide demonstrated significantly greater reductions in blood pressure compared to all dual combinations of its components- Amturnide combines the only approved direct renin… -
Media Release
Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
-
Media Release
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the… -
Media Release
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
November 2010
-
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
Elimination of 1,400 General Medicines field force positions effective January 1 to align organization with changes in portfolio and evolving healthcare market New organizational alignment creates… -
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
“Stand Together for AD: Strength and Support for Alzheimer’s” at AlzheimersDisease.com empowers caregivers with new resources and tools to help navigate challenges of caring for a loved one with…